Autopsy report · NCT03287908

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

“business decision, not safety reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 5 years 8 months before it stopped.
• 174 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Amgen

Sponsor type

Industry

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

AMG 701; Pomalidomide; Dexamethasone

Participants

174

Sites

34

Countries

Australia, Canada, Germany, Japan, Netherlands, United States

Trials that died the same way

• Study of Poziotinib in Japanese Patients With NSCLC
  “Business decision, not related to safety.” (90% match in meaning)
• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
  “Business reasons and not based on any safety concerns.” (86% match in meaning)
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
  “Business reasons and not due to any safety concerns” (84% match in meaning)
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
  “Business reasons not related to safety” (81% match in meaning)
• Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury
  “Based on a business decision unrelated to any safety concerns.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.